SIX Swiss Exchange · Healthcare
Invest in Ypsomed stock from India
Indian and foreign residents can buy Ypsomed (YPSN) shares directly through Paasa.
By Paasa · Updated
Ypsomed at a glance
- Price
- CHF 366.00+CHF 2.80 (0.77%)
- Market cap
- CHF 4.81B
- Day range
- CHF 362.20 – CHF 366.80
- P/E
- 22.44
- Dividend yield
- 1.20%
- Volume
- 7.85K
- 1 month
- -8.59%
- 6 months
- +31.89%
- YTD
- +11.59%
- 1 year
- +17.12%
- 5 years
- +139.33%
Ypsomed statements, FY2022–FY2026
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | CHF 731.0M | CHF 748.9M | CHF 548.5M | CHF 497.5M | CHF 464.8M |
| Gross profit | CHF 314.6M | CHF 292.1M | CHF 189.1M | CHF 140.6M | CHF 113.8M |
| Operating income | CHF 246.1M | CHF 112.9M | CHF 86.2M | CHF 60.6M | CHF 28.6M |
| Net income | CHF 221.9M | CHF 87.5M | CHF 78.4M | CHF 51.3M | CHF 23.1M |
| Earnings per share | CHF 16.31 | CHF 6.41 | CHF 5.74 | CHF 3.82 | CHF 1.83 |
| EBITDA | CHF 326.4M | CHF 190.9M | CHF 161.6M | CHF 137.5M | CHF 96.7M |
| Total assets | CHF 1.3B | CHF 1.3B | CHF 1.1B | CHF 861.9M | CHF 756.9M |
| Total debt | CHF 260.8M | CHF 267.0M | CHF 256.0M | CHF 157.0M | CHF 267.0M |
| Cash and short-term investments | CHF 28.6M | CHF 36.5M | CHF 74.0M | CHF 25.2M | CHF 17.0M |
| Shareholders' equity | CHF 748.1M | CHF 679.7M | CHF 617.7M | CHF 562.3M | CHF 392.5M |
| Operating cash flow | CHF 306.8M | CHF 148.2M | CHF 163.2M | CHF 129.5M | CHF 85.7M |
| Free cash flow | −CHF 16.3M | −CHF 128.9M | −CHF 32.1M | −CHF 39.6M | −CHF 41.7M |
| Capital expenditure | −CHF 323.1M | −CHF 277.1M | −CHF 195.3M | −CHF 169.2M | −CHF 127.4M |
Fiscal years as reported, the latest ending 31 Mar 2026. Figures in CHF; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Galenica | GALE.SW | CHF 82.25 | CHF 4.10B |
| Siegfried | SFZN.SW | CHF 72.00 | CHF 3.15B |
| Tecan | TECN.SW | CHF 234.40 | CHF 2.97B |
| BB Biotech | BION.SW | CHF 51.90 | CHF 2.86B |
| Medacta | MOVE.SW | CHF 114.20 | CHF 2.27B |
| SKAN | SKAN.SW | CHF 70.70 | CHF 1.59B |
| Cosmo Pharmaceuticals | COPN.SW | CHF 58.70 | CHF 1.01B |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Ypsomed from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to CHF when you buy.
Step 3
Search YPSN and buy
Find Ypsomed by name or by its ticker, YPSN, and place your order.
Why invest in Ypsomed from India
What Ypsomed does
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. Ypsomed operates in the Medical - Specialties industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Ypsomed stock from India?
Yes. Indian residents and NRIs can buy Ypsomed (YPSN) shares directly through Paasa. Ypsomed is listed on the SIX Swiss Exchange, in the Medical - Specialties industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell Ypsomed shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the CHF/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.